**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 71402

**Manuscript Type:** LETTER TO THE EDITOR

**Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation**

Razok A *et al*. SGLT2 inhibitor induced EDKA

Almurtada Razok, Fateen Ata, Sara Mohamed Ibrahim Ahmed, Dabia Hamad S H Al Mohanadi

**Almurtada Razok, Fateen Ata, Sara Mohamed Ibrahim Ahmed, Dabia Hamad S H Al Mohanadi,** Department of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar

**Dabia Hamad S H Al Mohanadi,** Department of Endocrinology, Hamad Medical Corporation, Doha 3050, Qatar

**Author contributions:** Razok A, Ata F, and Ahmed SMI wrote the letter; Al Mohanadi DHSH revised the letter**.**

**Corresponding author: Fateen Ata, BSc, MBBS, MD, Doctor,** Department of Internal Medicine, Hamad Medical Corporation, Al Rayyan Street, Bin Omran Area, Al Rayyan, Doha 3050, Qatar. docfateenata@gmail.com

**Received:** September 6, 2021

**Revised:** December 5, 2021

**Accepted:** February 10, 2022

**Published online:**

**Abstract**

Euglycemic diabetic ketoacidosis (EDKA) is a well-known complication of sodium-glucose co-transporter 2 inhibitors, and many cases with variable onset following the initiation of these agents are reported before, with a median onset of approximately 2 wk. This letter discusses a 45-year-old lady who initially presented with ischemic stroke but developed EDKA 4 d after starting empagliflozin, a rare occurrence. The patient had severe metabolic acidosis that necessitated admission into the intensive care unit. Prompt discontinuation of empagliflozin and DKA management resulted in clinical recovery.

**Key Words:** Euglycemic diabetic ketoacidosis; Sodium-glucose co-transporter 2 inhibitors; Type 2 diabetes mellitus; Empagliflozin

Razok A, Ata F, Ahmed SMI, Al Mohanadi DHSH. Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation. *World J Diabetes* 2022; In press

**Core Tip:** With a steady surge in the prescription of sodium-glucose co-transporter 2 inhibitors (SGLT2-i) in medical conditions including type 2 diabetes mellitus (DM), type 1 DM, and heart failure, there are increasingly reported cases of euglycemic diabetic ketoacidosis (EDKA) with their use. EDKA in the context of SGLT2-i use is reported in various patients with different precipitating factors, some even with no inciting event. One of the rarely reported inciting events is stroke. Another aspect of SGLT2-i induced EDKA which remains relatively less understood is the time of initiation of the drug to the development of EDKA. In our patient, severe EDKA developed within 4 d of empagliflozin initiation, necessitating intensive care and discontinuation of empagliflozin, resulting in complete recovery regarding the EDKA.

**TO THE EDITOR**

With great interest, we read the recent article "Euglycemic diabetic ketoacidosis: A missed diagnosis" by Nasa *et al*[1]. The authors have described various factors that can potentiate euglycemic diabetic ketoacidosis (EDKA) in sodium-glucose co-transporter 2 inhibitor (SGLT2-i) use. There is a steady increase in EDKA reports secondary to SGLT2-i. Most of the articles mention a precipitating factor behind the development of EDKA in patients taking SGLT2-i. More extensive studies mention no or unknown precipitating factor in 16%-51% of cases[2,3]. This creates a need to explore a possible direct link of SGLT2-i in the development of EDKA in an otherwise healthy patient with diabetes. Acute vascular events such as stroke are infrequent inciting events for EDKA in the setting of SGLT2-i use.

We recently encountered an interesting case of a patient with type 2 diabetes mellitus (T2DM) who was admitted with acute stroke and developed EDKA within 4 d of initiation of empagliflozin.

A 45-year-old woman presented with sudden onset left arm weakness and slurred speech with facial droop. Magnetic resonance imaging revealed a right basal ganglia acute infarction, in addition to left parietal subcortical microangiopathic changes. The patient had a history of breast carcinoma, treated with mastectomy and maintenance tamoxifen. She also had T2DM and was prescribed sitagliptin/metformin 50/1000 mg two tablets daily. However, the patient was non-compliant with the medication and was not checking her blood sugar regularly.

The patient was started on dual antiplatelet therapy (aspirin 100 mg and clopidogrel 75 mg once daily) after establishing the diagnosis of an acute stroke. Her HbA1c was 14%, confirming a poor control of her diabetes. To manage her poorly controlled diabetes mellitus, sitagliptin/metformin was continued, with the addition of insulin glargine 12 units at bedtime and empagliflozin 10 mg once daily.

Four days later, the patient developed vomiting and generalized fatigue. Arterial blood gas showed severe metabolic acidosis with a pH of 6.9 and bicarbonate level of 3 mEq/L (reference range: 22-26 mEq/L). Serum B-hydroxy butyrate was higher than the reported threshold of 9.60 mmol/L (reference range: 0.03-0.3). Her blood glucose level at the time was 10.3 mmol/L (reference range: 3.3-5.5), and her urine dipstick showed +4 ketone. She was diagnosed with severe EDKA and was shifted to the medical intensive care unit for further management and treatment

Regular insulin infusion and intravenous fluids were initiated, and a right internal jugular line was inserted for monitoring and resuscitation. Her arterial blood gas was measured every 2 h, and serum ketones were measured daily. Forty-eight hours later, the patient's condition improved, and she started tolerating oral feed. Her ABG results showed significant improvement with the closure of the anion gap (Table 1). She was started on subcutaneous glargine 20 units daily and insulin as part 7 units three times a day.

The patient was consequently shifted back to the care of the general medicine team, where her glycemic control was monitored closely. After ensuring the patient's fitness and stability, she was transferred to a physical and occupational therapy rehabilitation facility.

Our case highlights that in the presence of a precipitating factor, SGLT2-i drugs can cause an early and severe EDKA. We recommend that wherever other choices are available, initiation of SGLT2-i should be delayed until patients are otherwise healthy and not admitted with an acute event. SGLT2-i medications should ideally be started in an outpatient setting, and the patients should be counseled not to rely on blood glucose and seek immediate medical attention when experiencing symptoms of DKA.

**REFERENCES**

1 **Nasa P**, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. *World J Diabetes* 2021; **12**: 514-523 [PMID: 33995841 DOI: 10.4239/wjd.v12.i5.514]

2 **Clark A**, Mohammed AS, Raut A, Moore S, Houlden R, Awad S. Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital. *Can J Diabetes* 2021; **45**: 214-219 [PMID: 33046401 DOI: 10.1016/j.jcjd.2020.08.100]

3 **Ata F**, Yousaf Z, Khan AA, Razok A, Akram J, Ali EAH, Abdalhadi A, Ibrahim DA, Al Mohanadi DHSH, Danjuma MI. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. *Sci Rep* 2021; **11**: 10293 [PMID: 33986421 DOI: 10.1038/s41598-021-89752-w]

**Footnotes**

**Conflict-of-interest statement:** The authors have no actual or potential conflict of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American College of Physicians, 03770816.

**Peer-review started:** September 6, 2021

**First decision:** December 4, 2021

**Article in press:**

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** Qatar

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Papazafiropoulou A **S-Editor:** Zhang H **L-Editor:** Wang TQ **P-Editor:** Zhang H

**Table 1 Laboratory investigations of the patient during euglycemic diabetic ketoacidosis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Investigation** | **Onset** | **24 h** | **48 h** | **Reference** |
| PH | 6.9 | 7.32 | 7.42 | 7.35-7.45 |
| HCO3 (mmol/L) | 3 | 12.5 | 20.6 | 22-29 |
| Glucose (mmol/L) | 10.3 | 10.8 | 6.4 | 3.3-5.5 |
| Sodium (mmol/L) | 140 | 137 | 139 | 133-146 |
| Potassium (mmol/L) | 3.8 | 3.2 | 3.4 | 3.5-5.3 |
| Chloride (mmol/L) | 101 | 111 | 110 | 95-108 |
| Anion Gap | 36 | 13.5 | 8.4 | 10-12 |
| Lactate (mmol/L) | 1.3 | 0.7 | 0.9 | 0.36-1.6 |
| B-hydroxybutyrate (mmol/L) | > 9.60 | 1.22 | 0.11 | 0.03-0.3 |